Stories written by

Rebecca Aicheler, The Conversation

A new antibody treatment may offer protection against severe Covid-19 for up to 18 months

AstraZeneca's durable monoclonal antibody treatment has shown promise in phase 3 clinical trials.

Rebecca Aicheler, The Conversation
· Oct 22, 2021 · 11:30 pm
Why you shouldn’t skip the second dose of your Covid-19 vaccine

Research suggests a single dose of the AstraZeneca is only 33% protective against the Delta variant.

Rebecca Aicheler, The Conversation
· Jun 29, 2021 · 07:30 pm